glp-1 and sarcopenia glp 1 Adverse effects of class drugs. Gastrointestinal issues are Sarcopenia in the era of – Malnutrition and Sarcopenia as Reasons

P.AlvesD.et al (2020)

Two other pharmaceutical companies have their own oral GLP-1 drugs in the works: Orforglipron: Developed by Eli Lilly, its in Phase 3 clinical trials for treating type 2 diabetes and obesity, with an expected September 2025 completion

Gastric inhibitory polypeptide (GIP) and insulin in obesity: increased response to stimulation and defective feedback control of serum levels

Just as you should not solely rely on medication for weight loss efforts, the same should be said about supplements and peptides

In addition, GLP-1 can slow gastric emptying, reduce appetite in patients and thus reduce body mass, control blood pressure, regulate blood lipids and protect cardiovascular function, and has a low risk of hypoglycemia

Mechanistic evaluation may include observation of compound interaction with signaling cascades involved in redox homeostasis, enzymatic activity, and molecular transport processes